HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
CCCR Research Studies
1 - 37 of 37
22LL011; Epcoritamab in B-cell Neoplasms
CHOP in collaboration with AbbVie, is conducting a study for pediatric patients from 1 year of age to 25 years of age with relapsed or refractory aggressive mature B-cell neoplasms (including diffuse large B-cell lymphoma, Burkitt and Burkitt-like lymphoma/leukemia).
AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia
This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R).
AAML1921; Bosutinib for Chronic Myeloid Leukemia
The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).
ABA3 GVHD ProRx post Allo HACT
Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors
This study involves an investigational cellular therapy called Afamitresgene Autoleucel.
Alpelisib in PIK3CA Associated Lymphatic Malformations
This study has several parts and involves taking a study drug called alpelisib.Alpelisib in PIK3CA-related overgrowth syndrome
The purpose of this study is to find out if alpelisib (BYL719; the “study drug”), is safe and effective (can help) people who have PIK3CA-related overgrowth spectrum (PROS) disease.
BA3011 for advanced solid tumors
This study involves taking a study drug called BA3011. The overall goal of this study is to see if BA3011 is a possible treatment for patients with sarcoma.
Cabo/Ifos in Ewing Sarcoma and Osteosarcoma (CaIRS trial)
This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy.
Cancer Genomic Testing Study
The Department of Genomic Diagnostics is interested in studying genetic/molecular testing results from patients who are diagnosed with cancer as confirmed by genetic testing done at CHOP.
Carfilzomib in ALL
This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen.
Chemotherapy-induced Nausea and Vomiting Control
The overall goal of this study is to find the best strategies used by parents and patients for managing these symptoms when receiving maintenance therapy.
Copanlisib in Solid Tumors or Lymphoma
The purpose of this study is to find out what is the right dose of copanlisib in children and adolescents, and if your disease responds to this new drug.
Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Relapsed AML
This study involves taking a study drug called venetoclax with or without standard of care chemotherapy.
GD2CART for Osteosarcoma or Neuroblastoma
This study enrolls patients that have been diagnosed with osteosarcoma or neuroblastoma that has come back (relapsed) or has not responded to standard treatments (refractory).Humanized CART19 Phase 2 Trial
This purpose of this study is to determine the efficacy of humanized CD19 CAR T cells (huCART19) in pediatric and young adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
INBRX-109 in Ewing Sarcoma and Gastrointestinal Stromal Tumor (GIST)
This study involves taking a study drug called INBRX-109.
Larotrectinib RAI Thyroid (LANTERN)
This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and NTRK fusion.
Lurbinectedin in Ewing Sarcoma
This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.
Lutathera in Somatostatin Neuroendocrine Tumors
This study involves taking a study drug called Lutathera.
NEPENTHE - Next Generation Personalized Neuroblastoma Therapy
This is a clinical trial for patients with neuroblastoma that has returned (relapsed) or has not responded to standard treatment.
ON-TRK
The goal of this observational study is to describe the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment.
Oral Asciminib in CML
This study involves taking a study drug called asciminib.
Palbociclib, Irinotecan, and Temozolomide in Ewing Sarcoma
The purpose of the Phase 2 portion of this study is to evaluate the safety and efficacy of the study drug called palbociclib when given in combination with two other drugs (temozolomide and irinotecan) in patients with Ewing sarcoma and when given in combination with topotecan and cyclophosphamide in patients with neuroblastoma.
Repotrectinib for ALK, ROS1, or NTRK1-3 Alterations
The purpose of this study is to test the safety and efficacy of the investigational drug called repotrectinib in children whose cancers have specific genetic changes (in the ALK, ROS1, or NTRK1-3 genes).
Selpercatinib in Solid or CNS tumors with RET-Alterations
The purpose of this study is to test the safety and efficacy of the investigational drug called Selpercatinib in children whose cancers have a specific genetic change (RET-fusion or RET-mutation).
Selpercatinib in Thyroid Cancer (Collaboration with the International Thyroid Oncology Group)
This study involves taking a study drug called selpercatinib.
Selpercatinib RAI Thyroid (RAISE Trial)
Synovial Sarcoma Registry / Biospecimen Repository
The purpose of this study is to establish a registry and biorepository for synovial sarcoma patients by collecting and storing data and biospecimens, such as blood, saliva and/or buccal (cheek) swabs, and tumor tissue.
TAPISTRY
The purpose of this study is to evaluate the effects, good or bad, of targeted therapies or immunotherapy (drugs that help the body's immune system fight cancer cells) in patients who have solid tumors with specific genetic alterations or with a high number of mutations.
Tara-002 in Lymphatic Malformations
This study is for people with growing abnormal lymph vessels called lymphatic malformations (LMs).
TAS-117 in Tumors Harboring Germline PTEN Inactivating Mutations
Study is to see if TAS-117 is a possible treatment for advanced cancers with germline mutations in the PTEN gene.
Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids
This study has two parts. Part A enrolls patients who have been diagnosed with a solid tumor, lymphoma or desmoid tumor that has either come back ("relapsed") or does not respond to therapy ("is refractory"). Part B enrolls patients with a relapsed or refractory Ewing sarcoma, desmoid tumor, osteosarcoma, liver tumor, Wilms tumor, or tumors with changes in a gene family known as the Wnt pathway.
The LiFFT Study
This study involves taking a study drug called lurbinectedin.
Tiragolumab and Atezolizumab in SMARCB1 or SMARCA4 Deficient Tumors
This study enrolls patients that have been diagnosed with SMARCB1 or SMARCB4 deficient cancer that has either come back (“relapsed”) or does not respond to therapy (“is refractory”) or have been newly diagnosed with a SMARCB1 or SMARCB4 deficient cancer that has no known standard treatment.
Uproleselan in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Mixed Phenotype Acute Leukemia (MPAL)
This study enrolls patients that have been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or mixed phenotype acute leukemia (MPAL) that has either come back (‘relapsed’) or does not respond to therapy (‘refractory’).